Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiome Modulation and Pembrolizumab in Pancreatic Cancer
NCT05462496Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2023
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in pancreatic adenocarcinoma (PDAC), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2023; status: recruiting.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05462496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462496.